Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus – a clinician’s guide to the science informing current practice

References

• Griffith RS. Introduction to vancomycin. Clin Infect Dis 1981;3(Supp 2):S200-4
   Google Scholar
• Leeper MH, Dowling HF, Jackson GG, et al. Effect of antibiotic usage in the hospital in the incidence of antibiotic-resistant strains among personnel carrying Staphylococci. J Lab Clin Med 1953;43:832
   Google Scholar
• Moellering RC. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42(Supp 1):S3-4
   Google Scholar
• Rolinson GN. Celbenin – resistant Staphylococci. BMJ 1961;1(5219):125-6
   Google Scholar
• Matsuhashi M, Song MD, Ishino F, et al. Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol 1986;167(3):975-80
   PubMed Web of Science ®Google Scholar
• Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 1984;158(2):513-16
   PubMed Web of Science ®Google Scholar
• Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000;44(6):1549-55
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23(3):616-87
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42(5):647-56
   PubMed Web of Science ®Google Scholar
• Graber CJ, Wong MK, Carleton HA, et al. Intermediate vancomycin susceptibility in a community-associated MRSA Clone. Emerg Infect Dis 2007;13(3):491-3
   Google Scholar
• Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350(9092):1670-3
   PubMed Web of Science ®Google Scholar
• Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1(3):147-55
   PubMedGoogle Scholar
• Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38(4):521-8
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44(9):1208-15
   PubMed Web of Science ®Google Scholar
• Vancomycin Rationale for the EUCAST clinical breakpoints. version 2.1. EUCAST 2010. Available from: www.eucast.org [Last accessed 2 February 2015]
   Google Scholar
• CDC. Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR CDC Surveillance Summaries 2002;51(26):565-7
   Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348(14):1342-7
   PubMed Web of Science ®Google Scholar
• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319(3):157-61
   PubMed Web of Science ®Google Scholar
• Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93(2):195-8
   Google Scholar
• Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49(1):470-2
   Google Scholar
• Limbago BM, Kallen AJ, Zhu W, et al. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol 2014;52(3):998-1002
   PubMed Web of Science ®Google Scholar
• Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008;57(1):72-9
   Google Scholar
• Saadat S, Solhjoo K, Norooz-Nejad M-J, Kazemi A. VanA and vanB positive vancomycin-resistant Staphylococcus aureus among clinical isolates in Shiraz, south of Iran. Oman Med J 2014;29(5):335-9
   Google Scholar
• Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013;382(9888):205
   PubMed Web of Science ®Google Scholar
• Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014;370(16):1524-31
   PubMed Web of Science ®Google Scholar
• Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009;47(6):1628-30
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53(7):3162-5
   PubMed Web of Science ®Google Scholar
• Keel RA, Sutherland CA, Aslanzadeh J, et al. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis 2010;68(3):326-9
   Web of Science ®Google Scholar
• Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant staphylococcus aureus: Comparison of Etest and three automated testing methods. J Clin Microbiol 2013;51(7):2077-81
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution and antimicrobial susceptibility tests for bacteria that grow aerobically. 9 edition. Clinical and Laboratory Standards Institute; Wayne, PA: 2012
   Google Scholar
• Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009;47(7):2013-17
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42(Supp 1):S13-24
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing -Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. EUCAST 2015. Available from: www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf [Last accessed 2 February 2015]
   Google Scholar
• Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23(1):99-139
   PubMed Web of Science ®Google Scholar
• Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2011;47(4):399-400
   Google Scholar
• Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011;49(1):177-83
   Google Scholar
• Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39(7):2439-44
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46(9):2950-4
   PubMedGoogle Scholar
• Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47(6):1640-4
   Google Scholar
• Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009;53(8):3447-52
   PubMed Web of Science ®Google Scholar
• Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999;353(9164):1587-8
   PubMedGoogle Scholar
• Ho C-M, Hsueh P-R, Liu C-Y, et al. Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan - SMART program. Eur J Clin Microbiol Infect Dis 2003;29(4):383-9
   Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44(11):3883-6
   PubMed Web of Science ®Google Scholar
• Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60(4):788-94
   PubMed Web of Science ®Google Scholar
• Sader HS, Fey PD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009;53(10):4127-32
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98
   PubMedGoogle Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49(3):325-7
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moellering RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006;42(Supp 1):S40-50
   Google Scholar
• Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can’t get there from here. Clin Infect Dis 2011;52(8):969-74
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49(4):507-14
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54(6):755-71
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentration. J Infect Dis 2011;204(3):340-7
   PubMed Web of Science ®Google Scholar
• Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007;104(22):9451-6
   PubMed Web of Science ®Google Scholar
• McAleese F, Wu SW, Sieradzki K, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J Bacteriol 2006;88(3):1120-33
   Google Scholar
• Vidaillac C, Gardete S, Tewhey R, et al. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J Infect Dis 2013;208(1):67-74
   Google Scholar
• Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol 2014;21:575-82
   PubMed Web of Science ®Google Scholar
• Passalacqua KD, Satola SW, Crispell EK, Read TD. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Antimicrob Agents Chemother 2012;56(10):5212-522
   PubMed Web of Science ®Google Scholar
• Howden BP, McEvoy CRE, Allen DL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011;7(11):e1002359
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos GM, Moellering RCJr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002;46(5):1492-502
   PubMed Web of Science ®Google Scholar
• Neoh H-M, Cui L, Yuzawa H, et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 2008;52(1):45-53
   Google Scholar
• Cui L, Neoh H-M, Shoji M, Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009;53(3):1231-4
   PubMed Web of Science ®Google Scholar
• Cui L, Isii T, Fukuda M, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2010;54(12):5222-33
   PubMed Web of Science ®Google Scholar
• Gao W, Chua K, Davies JK, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 2010;6(6):e1000944
   PubMed Web of Science ®Google Scholar
• Gao W, Cameron DR, Davies JK, et al. The RpoB H481Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus. J Infect Dis 2013;207(6):929-39
   PubMed Web of Science ®Google Scholar
• Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006;24(12):1551-7
   PubMed Web of Science ®Google Scholar
• Hilchie AL, Wuerth K, Hancock REW. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 2013;9(12):761-8
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos GM, Fowler VG, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005;49(7):2687-92
   PubMed Web of Science ®Google Scholar
• Wu T, Yeaman MR, Bayer AS. In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates. Antimicrob Agents Chemother 1994;38(4):729-32
   Google Scholar
• Mishra NN, Bayer AS, Moise PA, et al. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 2012;206(8):1160-7
   PubMed Web of Science ®Google Scholar
• Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55(9):4012-18
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Cui L, Katayama Y, et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011;49(7):2680-4
   PubMed Web of Science ®Google Scholar
• Matsuo M, Hishinuma T, Katayama Y, et al. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother 2011;55(9):4188-95
   PubMed Web of Science ®Google Scholar
• Cui L, Tominaga E, Neoh H-M, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(3):1079-82
   PubMed Web of Science ®Google Scholar
• Alam MT, Petit RA, Crispell EK, et al. Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association. Genome Biol Evol 2014;6(5):1174-85
   PubMed Web of Science ®Google Scholar
• Faville RJ, Zaske DE, Kaplan EL, et al. Staphylococcus aureus endocarditis - Combined therapy with vancomycin and rifampin. JAMA 1978;240(18):1963-5
   Google Scholar
• Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994;33(5):959-67
   PubMed Web of Science ®Google Scholar
• Jung YJ, Koh Y, Hong S-B, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38(1):175-80
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(7):2463-7
   PubMed Web of Science ®Google Scholar
• Jang H-C, Kim S-H, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009;49(3):395-401
   PubMed Web of Science ®Google Scholar
• Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007;45(2):329-32
   Google Scholar
• Burke SL, Rose WE. New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother 2014;15(4):483-91
   PubMed Web of Science ®Google Scholar
• Harbarth S, Dach von E, Pagani L, et al. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 2015;70(1):264-72
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Okumura CY, Thienphrapa W, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med 2014;92(2):139-49
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014;36(10):1317-33
   PubMed Web of Science ®Google Scholar
• Mehta S, Singh C, Plata KB, et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012;56(12):6192-200
   PubMed Web of Science ®Google Scholar
• Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011;66(5):1057-60
   PubMed Web of Science ®Google Scholar
• Peschel A, Jack RW, Otto M, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor mprf is based on modification of membrane lipids with lysine. J Exp Med 2011;193(9):1067-76
   Google Scholar
• Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Update 2014;17(1-2):1-12
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54(5):621-9
   PubMed Web of Science ®Google Scholar
• Sánchez García M, la Torre De MÁ, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303(22):2260-4
   PubMed Web of Science ®Google Scholar
• Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother 2000;44(9):2530-3
   PubMed Web of Science ®Google Scholar
• Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006;50(7):2500-5
   PubMed Web of Science ®Google Scholar
• Kehrenberg C, Ojo KK, Schwarz S. Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from Staphylococcus sciuri. J Antimicrob Chemother 2004;54(5):936-9
   PubMed Web of Science ®Google Scholar
• Quiles-Melero I, Gómez-Gil R, Romero-Gómez MP, et al. Mechanisms of linezolid resistance among Staphylococci in a tertiary hospital. J Clin Microbiol 2013;51(3):998-1001
   Google Scholar
• Locke JB, Rahawi S, LaMarre J, et al. Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob Agents Chemother 2012;56(1):332-40
   PubMed Web of Science ®Google Scholar
• Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64(6):1506-14
   PubMed Web of Science ®Google Scholar
• Shore AC, Brennan OM, Ehricht R, et al. Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. Antimicrob Agents Chemother 2010;54(12):4978-84
   Google Scholar
• Kehrenberg C, Aarestrup FM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob Agents Chemother 2007;51(2):483-7
   Google Scholar
• Dai L, Wu C-M, Wang M-G, et al. First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces. Antimicrob Agents Chemother 2010;54(9):3953-5
   PubMed Web of Science ®Google Scholar
• Diaz L, Kiratisin P, Mendes RE, et al. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012;56(7):3917-22
   PubMed Web of Science ®Google Scholar
• Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011;66(Supp 3):iii11-18
   Google Scholar
• Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013;42(5):450-5
   Google Scholar
• Saravolatz SN, Martin H, Pawlak J, et al. Ceftaroline-heteroresistant Staphylococcus aureus. Antimicrob Agents Chemother 2014;58(6):3133-6
   Google Scholar
• Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010;67(12):983-93
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012;39(3):240-6
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang Y-C, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014;59(1):51-61
   PubMed Web of Science ®Google Scholar
• Damodaran SE, Madhan S. Telavancin: A novel lipoglycopeptide antibiotic. J Pharmacol Pharmacother 2011;2(2):135-7
   PubMedGoogle Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370(23):2180-90
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370(23):2169-79
   PubMed Web of Science ®Google Scholar
• Sahm DF, Deane J, Bien PA, et al. Results of the surveillance of tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 2015;81(2):112-18
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309(6):559-69
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009;63(3):489-92
   Google Scholar
• Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA) in particular, heterogeneous GISA. J Clin Microbiol 2008;46(9):3042-7
   Google Scholar
• Lexicomp Online, Lexi-Drugs Online, Hudson, Ohio: Lexi-comp, Inc.; 2014 [ Last accessed 2 February 2015
   Google Scholar
• Howden BP, Grayson MLG. Dumb and dumber – the potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006;42:394-400
   PubMed Web of Science ®Google Scholar